PMTA and MRTP: navigating the path to FDA approval for reduced-risk products

PMTA and MRTP: navigating the path to FDA approval for reduced-risk products

1,500.00$

Contents:

  • Executive summary
  • Background
  • Legal framework
  • The PMTA and MRTPA for iQOS and Heets
  • Premarket Tobacco Product Applications (PMTA)
  • PMI’s PMTA application
  • What we expect
  • Modified Risk Tobacco Product Applications (MRTPA)
  • PMI’s MRTPA
  • What do we expect
  • A practical example: snus
  • Potential regulation of HnB beyond the PMTA
  • The substantial equivalence route: an alternative to PMTAs

Description

As PMI’s iQOS comes under consideration by the US FDA, we examine the hurdles it – and other – heated tobacco and e-cigarette products will have to clear to obtain authorisation for commercialisation and reduced-risk claims.

ECigIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of ECigIntelligence, does not accept any liability or responsibility for information or views published.
Please see this page for a detailed description of our methodology.